Search Results

The Melanoma Research Alliance, the world’s leading non-profit funder of melanoma research, announced its $12.6 million commitment to fund melanoma research supporting more than 30 scientists at leading academic and medical institutions in the United States and across the globe.

The Lupus Research Alliance announced the recipients of the 2024 Lupus Insight Prize to Marko Radic, Ph.D., The University of Tennessee Health Science Center, and Georg Schett, M.D., Friedrich-Alexander-Universität Erlangen-Nürnberg, for their groundbreaking discoveries in utilizing CAR T cell therapy to potentially revolutionize lupus treatment.

23andMe Holding Co., a leading genetic health and biopharmaceutical company, and the Colorectal Cancer Alliance, the largest nonprofit organization dedicated to ending colorectal cancer, announced a collaboration to help advance research on colorectal cancer in the Black/African American community.

Ono Pharmaceutical Co., Ltd. announced that it entered into a five-year, university-wide strategic research alliance agreement with Harvard University aiming at validating novel therapeutic targets.

The Lupus Research Alliance is pleased to announce the recent recipients of the Lupus Mechanisms and Targets Award, whose research will investigate molecular pathways or targets that will lead to new or improved therapies for individuals with systemic lupus erythematosus.

University Cancer & Blood Center, a leading oncology and hematology practice for Northeast Georgia, and University Health Alliance, a multi-disciplinary practice focusing on prevention and coordinated care, announce the opening of their High-Risk GI Clinic.

Zomedica Corp., a veterinary health company offering diagnostic and therapeutic products for equine and companion animals, completed the expansion of its global manufacturing and distribution facilities in Roswell, Georgia.

The Melanoma Research Alliance, the largest non-profit funder of melanoma research worldwide, welcomes the U.S. Food and Drug Administration decision to approve Iovance Biotherapeutics’ AMTAGVI™ for the treatment of patients with advanced melanoma in the second line treatment setting.

AN2 Therapeutics, Inc. today announced that it has received an exclusive license from the University of Georgia Research Foundation to advance the development of a boron-containing small molecule for Chagas disease.